Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $9.96 and last traded at $10.46, with a volume of 2930532 shares changing hands. The stock had previously closed at $11.45.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. BMO Capital Markets assumed coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective for the company. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective on the stock. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $46.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Finally, Piper Sandler decreased their price target on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Price Performance

The business’s 50-day moving average price is $13.20 and its 200-day moving average price is $23.23. The firm has a market capitalization of $1.18 billion, a PE ratio of -2.94 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 6,237 shares of company stock valued at $77,760 in the last ninety days. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $50,000. KBC Group NV grew its holdings in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the period. Finally, Summit Investment Advisors Inc. raised its position in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.